|
Late Stage Preclinical Projects |
Kevin D'Amour |
Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes |
$3,544,721 |
|
Clinical Trial Stage Projects |
Manasi Jaiman |
Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes |
$13,607,002 |
|
Disease Team Research I |
Allan Robins |
Cell Therapy for Diabetes |
$0 |
|
Quest - Discovery Stage Research Projects |
Alan Agulnick |
Preclinical development of an immune evasive islet cell replacement therapy for type 1 diabetes |
$1,470,987 |
|
Early Translational I |
Olivia Kelly |
Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product |
$5,405,397 |
|
Tools and Technologies I |
Evert Kroon |
Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. |
$827,072 |
|
Strategic Partnership I |
Howard Foyt |
Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes |
$9,475,070 |
|
Disease Team Planning |
Emmanuel Baetge |
Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes |
$48,950 |
|
Accelerated Development Pathway I |
Howard Foyt |
Clinical Development of a Cell Therapy for Diabetes |
$8,783,852 |
